Genome editing technology developer Precision BioSciences has raised $25.6m in funding from backers including Amgen and Baxter's corporate venturing units.
US-based genome editing company Precision BioSciences raised $25.6m yesterday in an oversubscribed series A round featuring pharmaceutical companies Amgen and Baxter.
Amgen and Baxter, which invested through their Amgen Ventures and Baxter Ventures subsidiaries, were joined by investment firm VenBio, which led the round, Fidelity Bioscience, a subsidiary of financial services firm Fidelity Investment, Osage University Partners, Longevity Fund and two undisclosed public market investors.
Precision BioSciences is developing of products based on its proprietary genome editing technology, Arcus, which…
